Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer

BACKGROUND: Docetaxel used for first-line treatment of advanced prostate cancer (PCa) is only marginally effective. We previously showed, using the LTL-313H subrenal capsule patient-derived metastatic PCa xenograft model, that docetaxel combined with Aneustat (OMN54), a multivalent plant-derived the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Qu, Sifeng, Ci, Xinpei, Xue, Hui, Dong, Xin, Hao, Jun, Lin, Dong, Clermont, Pier-Luc, Wu, Rebecca, Collins, Colin C, Gout, Peter W, Wang, Yuzhuo
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2018
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5877435/
https://ncbi.nlm.nih.gov/pubmed/29381682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.474
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados